［1］XIA C,DONG X,LI H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants［J］.Chinese Medical Journal,2022,135(5):584-590.
［2］樊博,齐盼,苏建志,等.河北医科大学第四医院前列腺癌患者的基线特征与生存分析［J］.中国癌症杂志,2020,30(8):620-625.FAN B,QI P,SU JZ,et al.Baseline characteristics and survival analysis of prostate cancer patients in the Fourth Hospital of Hebei Medical University［J］.China Oncology,2020,30(8):620-625.
［3］朱耀.中国去势抵抗性前列腺癌诊治专家共识［J］.浙江医学,2016,38(14):1133-1136，1145.ZHU Y.Expert consensus on the diagnosis and treatment of denervation-resistant prostate cancer in China［J］.Zhejiang Medicine,2016,38(14):1133-1136，1145.
［4］LIU JM,LIN CC,LIU KL,et al.Second-line hormonal therapy for the management of metastatic castration-resistant prostate cancer:a real-world data study using a claims database［J］.Scientific Reports,2020,10(1):4240.
［5］FREEDLAND SJ,DAVIS M,EPSTEIN AJ,et al.Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer(mCRPC) in the US medicare population［J］.Prostate Cancer and Prostatic Diseases,2024,27(2):327-333.
［6］SAAD F,CLARKE NW,OYA M,et al.Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer(PROpel):final prespecified overall survival results of a randomised,double-blind,phase 3 trial［J］.The Lancet Oncology,2023,24(10):1094-1108.
［7］LORD CJ,ASHWORTH A.PARP inhibitors:Synthetic lethality in the clinic［J］.Science,2017,355(6330):1152-1158.
［8］DAN R,VAN ALLEN EM,WU YM,et al.Integrative clinical genomics of advanced prostate cancer［J］.Cell,2015,161(5):1215-1228.
［9］RAO A,MOKA N,HAMSTRA DA,et al.Co-inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer-where are we now［J］.Cancers,2022,14(3):801.
［10］DE BONO J,MATEO J,FIZAZI K,et al.Olaparib for metastatic castration-resistant prostate cancer［J］.New England Journal of Medicine,2020,382(22):2091-2102.
［11］MATEO J,DE BONO JS,FIZAZI K,et al.Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and/or BRCA2 in the PROfound trial［J］.Journal of Clinical Oncology,2024,42(5):571-583.
［12］MATSUBARA N,NISHIMURA K,KAWAKAMI S,et al.Olaparib in patients with mCRPC with homologous recombination repair gene alterations:PROfound Asian subset analysis［J］.Japanese Journal of Clinical Oncology,2022,52(5):441-448.
［13］FIZAZI K,PIULATS JM,REAUME MN,et al.Rucaparib or physician’s choice in metastatic prostate cancer［J］.New England Journal of Medicine,2023,388(8):719-732.
［14］BRYCE AH,PIULATS JM,REAUME MN,et al.Rucaparib for metastatic castration-resistant prostate cancer(mCRPC):TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy［J］.Journal of Clinical Oncology,2023,41(6_suppl):18.
［15］DE BONO JS,MEHRA N,SCAGLIOTTI GV,et al.Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations(TALAPRO-1):an open-label,phase 2 trial［J］.The Lancet Oncology,2021,22(9):1250-1264.
［16］SMITH MR,SCHER HI,SANDHU S,et al.Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects(GALAHAD):a multicentre,open-label,phase 2 trial［J］.The Lancet Oncology,2022,23(3):362-373.
［17］SCHER HI,FIZAZI K,SAAD F,et al.Increased survival with enzalutamide in prostate cancer after chemotherapy［J］.New England Journal of Medicine,2012,367(13):1187-1197.
［18］POLKINGHORN WR,PARKER JS,LEE MX,et al.Androgen receptor signaling regulates DNA repair in prostate cancers［J］.Cancer Discovery,2013,3(11):1245-1253.
［19］SCHIEWER MJ,GOODWIN JF,HAN S,et al.Dual roles of PARP-1 promote cancer growth and progression［J］.Cancer Discovery,2012,2(12):1134-1149.
［20］GOODWIN JF,SCHIEWER MJ,DEAN JL,et al.A hormone-DNA repair circuit governs the response to genotoxic insult［J］.Cancer Discovery,2013,3(11):1254-1271.
［21］ASIM M,TARISH F,ZECCHINI HI,et al.Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer［J］.Nature Communications,2017,8:374.
［22］HUSSAIN MHA,KOCHERGINSKY M,AGARWAL N,et al.BRCAAway:A randomized phase 2 trial of abiraterone,olaparib,or abiraterone+olaparib in patients with metastatic castration-resistant prostate cancer(mCRPC) bearing homologous recombination-repair mutations(HRRm)［J］.Journal of Clinical Oncology,2024,42(4_suppl):19.
［23］CHI KN,RATHKOPF DE,SMITH MR,et al.Phase 3 MAGNITUDE study:First results of niraparib(NIRA) with abiraterone acetate and prednisone(AAP) as first-line therapy in patients(pts) with metastatic castration-resistant prostate cancer(mCRPC) with and without homologous recombination repair(HRR) gene alterations［J］.Journal of Clinical Oncology,2022,40(6_suppl):12.
［24］CHI KN,SANDHU S,SMITH MR,et al.Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations:second interim analysis of the randomized phase Ⅲ MAGNITUDE trial［J］.Annals of Oncology,2023,34(9):772-782.
［25］CHI KNN,CASTRO E,ATTARD G,et al.LBA85 Niraparib(NIRA) with abiraterone acetate plus prednisone(AAP) as first-line(1L) therapy in patients(pts) with metastatic castration-resistant prostate cancer(mCRPC) and homologous recombination repair(HRR) gene alterations:Three-year update and final analysis(FA) of MAGNITUDE［J］.Annals of Oncology,2023,34:S1326.
［26］AGARWAL N,AZAD AA,CARLES J,et al.Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer(TALAPRO-2):a randomised,placebo-controlled,phase 3 trial［J］.The Lancet,2023,402(10398):291-303.
［27］RAO A,HELLER G,RYAN CJ,et al.Alliance A031902(CASPAR):A randomized phase(ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer(mCRPC)［J］.Journal of Clinical Oncology,2023,41(6_suppl):TPS277.
［28］JIAO S,XIA W,YAMAGUCHI H,et al.PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression［J］.Clinical Cancer Research,2017,23(14):3711-3720.
［29］YU EY,PIULATS JM,GRAVIS G,et al.Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer:Long-term results from the phase 1b/2 KEYNOTE-365 cohort A study［J］.European Urology,2023,83(1):15-26.
［30］ANTONARAKIS ES,PARK SH,GOH JC,et al.Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer:The randomized,open-label,phase Ⅲ KEYLYNK-010 trial［J］.Journal of Clinical Oncology,2023,41(22):3839-3850.
［31］SUOMINEN MI,FAGERLUND KM,RISSANEN JP,et al.Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models［J］.Clinical Cancer Research,2017,23(15):4335-4346.
［32］EMMETT L,CRUMBAKER M,HO B,et al.Results of a prospective phase 2 pilot trial of 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression［J］.Clinical Genitourinary Cancer,2019,17(1):15-22.
［33］ZHENG F,ZHANG Y,CHEN S,et al.Mechanism and current progress of poly ADP-ribose polymerase(PARP) inhibitors in the treatment of ovarian cancer［J］.Biomedicine & Pharmacotherapy,2020,123:109661.
［34］SANDHU S,JOSHUA AM,EMMETT L,et al.LuPARP:Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer(mCRPC)［J］.Journal of Clinical Oncology,2023,41(16_suppl):5005.
［35］PHILIP CA,LASKOV I,BEAUCHAMP MC,et al.Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors［J］.BMC Cancer,2017,17(1):638.
［36］IBRAHIM YH,GARCIA-GARCIA C,SERRA V,et al.PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition［J］.Cancer Discovery,2012,2(11):1036-1047.
［37］POOK D,GEYNISMAN DM,CARLES J,et al.A phase Ⅰb,open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer［J］.Clinical Cancer Research,2023,29(17):3292-3300.
［38］KUMARESWARAN R,CHAUDARY N,JALUBA K,et al.Cyclic hypoxia does not alter RAD51 expression or PARP inhibitor cell kill in tumor cells［J］.Radiotherapy and Oncology,2015,116(3):388-391.
［39］HEGAN DC,LU Y,STACHELEK GC,et al.Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130［J］.Proceedings of the National Academy of Sciences of the United States of America,2010,107(5):2201-2206.
［40］KAPLAN AR,GUEBLE SE,LIU Y,et al.Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51［J］.Science Translational Medicine,2019,11(492):eaav4508.
［41］KIM JW,MCKAY RR,RADKE MR,et al.Randomized trial of olaparib with or without cediranib for metastatic castration-resistant prostate cancer:the results from national cancer institute 9984［J］.Journal of Clinical Oncology,2023,41(4):871-880.
［42］NA R,ZHENG SL,HAN M,et al.Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death［J］.European Urology,2017,71(5):740-747.
［43］TRINER D,GRAF R,GJOERUP O,et al.Real-world effectiveness of PARP inhibitors(PARP inhibitors) in metastatic castration-resistant prostate cancer(mCRPC) by genomic homologous recombination repair(HRR) alterations and homologous recombination deficiency signature(HRDsig)［J］.Journal of Clinical Oncology,2024,42(4_suppl):186.
［44］DONG B,FAN L,YANG B,et al.Use of circulating tumor DNA for the clinical management of metastatic castration-resistant prostate cancer:A multicenter,real-world study［J］.Journal of the National Comprehensive Cancer Network,2021,19(8):905-914.
［45］SANDHU SK,GOTTO G,VERA-BADILLO FE,et al.1835P a prospective study to determine the prevalence of DNA repair defects in patients(pts) with advanced prostate cancer(PC)［J］.Annals of Oncology,2023,34:S993.
［46］FALLAH J,XU J,WEINSTOCK C,et al.Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer:A US food and drug administration pooled analysis［J］.Journal of Clinical Oncology,2024,42(14):1687-1698.
［47］ATTARD G,SANDHU SK,RATHKOPF D,et al.1806P efficacy of niraparib and abiraterone acetate plus prednisone(NIRA+AAP) in homologous recombination repair gene-altered(HRR+) metastatic castration-resistant prostate cancer(mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial［J］.Annals of Oncology,2023,34:S976-S977.
［48］SCOTT RJ,MEHTA A,MACEDO GS,et al.Genetic testing for homologous recombination repair(HRR) in metastatic castration-resistant prostate cancer(mCRPC):challenges and solutions［J］.Oncotarget,2021,12(16):1600-1614.
［49］WANG J,ZHAO D,ZHAO J,et al.A0636-exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer［J］.European Urology,2024,85:S1569.